Neopterin production in relation to COVID-19 in the Haut-Ogooué Province, Gabon.
Age
Biomarker
COVID-19
Immunosenescence
Neopterin
SARS-CoV-2
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
13
10
2023
accepted:
19
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
epublish
Résumé
In sub-Saharan Africa, understanding of the immune process associated with the COVID-19 pandemic remains scarce. This study aimed to investigate the relationship between plasma neopterin concentrations and COVID-19 infection, focusing on changes over time and age-related changes in immune response. A retrospective case study was conducted during the first wave of COVID-19 from March to August 2020. Whole blood and associated symptoms and comorbidities were collected from patients of all ages and sexes. Concentrations of plasma neopterin were measured using a commercial competitive neopterin ELISA (Neopterin ELISA, IBL International GmbH, Germany). We analyzed data for 325 patients: 38% (n = 124) with COVID-19, and 62% (n = 201) without COVID-19, as a control group. We found that plasma neopterin concentrations were significantly higher in the COVID-19 group (mean value 45.1 nmol/L (SD 19)) than in the control group (mean value 33.8 nmol/L (SD 13)) (p = 0.004). In addition, neopterin levels decreased gradually over time in patients with COVID-19 (p < 0.001). Moreover, ROC analysis found that the best cut-off value for diagnosing COVID-19 patients based on plasma neopterin levels was 38.85 nmol/L with 70% sensitivity and 82% specificity (AUC, 0.74 [0.69-0.82], p < 0.05). We also found an increase in neopterin production with increasing age (p < 0.001). Our findings contribute to our growing understanding of neopterin levels as a promising biomarker for the detection of COVID-19 cases in sub-Saharan Africa.
Sections du résumé
BACKGROUND
BACKGROUND
In sub-Saharan Africa, understanding of the immune process associated with the COVID-19 pandemic remains scarce. This study aimed to investigate the relationship between plasma neopterin concentrations and COVID-19 infection, focusing on changes over time and age-related changes in immune response.
METHODS
METHODS
A retrospective case study was conducted during the first wave of COVID-19 from March to August 2020. Whole blood and associated symptoms and comorbidities were collected from patients of all ages and sexes. Concentrations of plasma neopterin were measured using a commercial competitive neopterin ELISA (Neopterin ELISA, IBL International GmbH, Germany).
RESULTS
RESULTS
We analyzed data for 325 patients: 38% (n = 124) with COVID-19, and 62% (n = 201) without COVID-19, as a control group. We found that plasma neopterin concentrations were significantly higher in the COVID-19 group (mean value 45.1 nmol/L (SD 19)) than in the control group (mean value 33.8 nmol/L (SD 13)) (p = 0.004). In addition, neopterin levels decreased gradually over time in patients with COVID-19 (p < 0.001). Moreover, ROC analysis found that the best cut-off value for diagnosing COVID-19 patients based on plasma neopterin levels was 38.85 nmol/L with 70% sensitivity and 82% specificity (AUC, 0.74 [0.69-0.82], p < 0.05). We also found an increase in neopterin production with increasing age (p < 0.001).
CONCLUSION
CONCLUSIONS
Our findings contribute to our growing understanding of neopterin levels as a promising biomarker for the detection of COVID-19 cases in sub-Saharan Africa.
Identifiants
pubmed: 39198763
doi: 10.1186/s12879-024-09766-3
pii: 10.1186/s12879-024-09766-3
doi:
Substances chimiques
Neopterin
670-65-5
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
872Informations de copyright
© 2024. The Author(s).
Références
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020;56:106054.
pubmed: 32534188
pmcid: 7286265
doi: 10.1016/j.ijantimicag.2020.106054
Feng W, Zong W, Wang F, Ju S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. Mol Cancer. 2020;19:100.
pubmed: 32487159
pmcid: 7264920
doi: 10.1186/s12943-020-01218-1
Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–9.
pubmed: 32015508
pmcid: 7094943
doi: 10.1038/s41586-020-2008-3
Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21:245–56.
pubmed: 33723416
pmcid: 7958099
doi: 10.1038/s41577-021-00522-1
Boechat JL, Chora I, Morais A, Delgado L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – current perspectives. Pulmonology. 2021;27:423–37.
pubmed: 33867315
pmcid: 8040543
doi: 10.1016/j.pulmoe.2021.03.008
Zhou X, Ye Q. Cellular Immune response to COVID-19 and potential Immune modulators. Front Immunol. 2021;12.
Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184:1671–92.
pubmed: 33743212
pmcid: 7885626
doi: 10.1016/j.cell.2021.02.029
Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11.
Zhang L, Guo H. Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. Adv Biomark Sci Technol. 2020;2:1–23.
pubmed: 33511330
pmcid: 7435336
Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19 – a systematic review. Life Sci. 2020;254:117788.
pubmed: 32475810
pmcid: 7219356
doi: 10.1016/j.lfs.2020.117788
Caruso FP, Scala G, Cerulo L, Ceccarelli M. A review of COVID-19 biomarkers and drug targets: resources and tools. Brief Bioinform. 2021;22:701–13.
pubmed: 33279954
doi: 10.1093/bib/bbaa328
Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26:107–8.
pubmed: 32934000
doi: 10.1136/bmjebm-2020-111536
Pingle S, Tumane R, Jawade A, Neopterin. Biomarker of cell-mediated immunity and potent usage as biomarker in silicosis and other occupational diseases. Indian J Occup Environ Med. 2008;12:107.
pubmed: 20040967
pmcid: 2796748
doi: 10.4103/0019-5278.44690
Ünüvar S, Aslanhan H. Clinical significance of increased serum neopterin in chronic kidney failure as a biomarker of cell-mediated immunity. J Med Biochem. 2019;38:1–5.
pubmed: 30820177
pmcid: 6298458
doi: 10.2478/jomb-2018-0019
Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for Immune System activation. Curr Drug Metab. 2002;3:175–87.
pubmed: 12003349
doi: 10.2174/1389200024605082
Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.
pubmed: 19029990
pmcid: 2724991
doi: 10.1038/nri2448
Eisenhut M. Neopterin in Diagnosis and Monitoring of Infectious Diseases. J Biomark. 2013;2013.
Husain N, Tokoro K, Popov JM, Naides SJ, Kwasny MJ, Buchman AL. Neopterin concentration as an index of Disease Activity in Crohn’s Disease and Ulcerative Colitis. J Clin Gastroenterol. 2013;47:246.
pubmed: 23269308
doi: 10.1097/MCG.0b013e3182582cdb
Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010;287:13–22.
pubmed: 19500901
doi: 10.1016/j.canlet.2009.05.008
Ozger HS, Dizbay M, Corbacioglu SK, Aysert P, Demirbas Z, Tunccan OG, et al. The prognostic role of neopterin in COVID-19 patients. J Med Virol. 2021;93:1520–5.
pubmed: 32860465
doi: 10.1002/jmv.26472
Robertson J, Gostner JM, Nilsson S, Andersson L-M, Fuchs D, Gisslen M. Serum neopterin levels in relation to mild and severe COVID-19. BMC Infect Dis. 2020;20:942.
pubmed: 33302893
pmcid: 7726600
doi: 10.1186/s12879-020-05671-7
Zheng B, Cao K-Y, Chan CPY, Choi JWY, Leung W, Leung M, et al. Serum neopterin for early assessment of severity of severe acute respiratory syndrome. Clin Immunol. 2005;116:18–26.
pubmed: 15925828
pmcid: 7106326
doi: 10.1016/j.clim.2005.03.009
Chauvin M, Larsen M, Quirant B, Quentric P, Dorgham K, Royer L et al. Elevated neopterin levels predict fatal outcome in SARS-CoV-2-Infected patients. Front Cell Infect Microbiol. 2021;11.
Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Cruz-Martins N, Batiha GE-S. The potential role of neopterin in Covid-19: a new perspective. Mol Cell Biochem. 2021;476:4161–6.
pubmed: 34319496
pmcid: 8317144
doi: 10.1007/s11010-021-04232-z
Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AEO, Nkengasong JN. COVID-19 in Africa: the spread and response. Nat Med. 2020;26:999–1003.
pubmed: 32528154
doi: 10.1038/s41591-020-0961-x
Mveang Nzoghe A, Padzys G-S, Maloupazoa Siawaya AC, Kandet Yattara M, Leboueny M, Avome Houechenou RM, et al. Dynamic and features of SARS-CoV-2 infection in Gabon. Sci Rep. 2021;11:9672.
pubmed: 33958601
pmcid: 8102484
doi: 10.1038/s41598-021-87043-y
Mveang Nzoghe A, Essone PN, Leboueny M, Maloupazoa Siawaya AC, Bongho EC, Mvoundza Ndjindji O, et al. Evidence and implications of pre-existing humoral cross‐reactive immunity to SARS‐CoV‐2. Immun Inflamm Dis. 2020;9:128–33.
pubmed: 33320447
pmcid: 7860591
doi: 10.1002/iid3.367
N’dilimabaka N, Mounguegui DM, Lekana-Douki SE, Yattara MK, Obame-Nkoghe J, Longo-Pendy NM, et al. Biochemical and hematological factors associated with COVID-19 severity among Gabonese patients: a retrospective cohort study. Front Cell Infect Microbiol. 2022;12:975712.
pubmed: 36619758
pmcid: 9816336
doi: 10.3389/fcimb.2022.975712
Lekana-Douki SE, N’dilimabaka N, Levasseur A, Colson P, Andeko JC, Zong Minko O, et al. Screening and whole genome sequencing of SARS-CoV-2 circulating during the First three waves of the COVID-19 pandemic in Libreville and the Haut-Ogooué Province in Gabon. Front Med. 2022;9:877391.
doi: 10.3389/fmed.2022.877391
Lekana-Douki SE, N’Dilimabaka N, Mbongo-Kama E, Kandet Yattara M, Mintsa Ndong A, Ngonga Dikongo AM, et al. Epidemiology of first cases of SARS-CoV-2 infection, from March to April 2020 and molecular characterization of the spike protein, in Gabon. F1000Res. 2022;11:205.
pubmed: 36451659
pmcid: 9672532
Abe H, Ushijima Y, Bikangui R, Zoa-Assoumou S, Ondo GN, Manouana GP, et al. Unrecognized introduction of SARS-CoV-2 variants of concern to Central Africa: Import and local transmission of B.1.1.7 in Gabon in the very early stage of the variant spread to the African continent. J Med Virol. 2021;93:6054–8.
pubmed: 34185327
pmcid: 8426813
doi: 10.1002/jmv.27164
Manouana GP, Nzamba Maloum M, Bikangui R, Oye Bingono SO, Ondo Nguema G, Honkpehedji JY, et al. Emergence of B.1.1.318 SARS-CoV-2 viral lineage and high incidence of alpha B.1.1.7 variant of concern in the Republic of Gabon. Int J Infect Dis. 2022;114:151–4.
pubmed: 34742926
doi: 10.1016/j.ijid.2021.10.057
Karabulut A, Şahin M. Inflammatory markers and neopterin levels in relation to mild COVID-19. Eur Rev Med Pharmacol Sci. 2023;27:8952–61.
pubmed: 37782204
Pizzini A, Kurz K, Santifaller J, Tschurtschenthaler C, Theurl I, Fuchs D, et al. Assessment of neopterin and indoleamine 2,3-dioxygenase activity in patients with seasonal influenza: a pilot study. Influenza Other Respir Viruses. 2019;13:603–9.
pubmed: 31489989
pmcid: 6800299
doi: 10.1111/irv.12677
Nyamweya S, Townend J, Zaman A, Steele SJ, Jeffries D, Rowland-Jones S, et al. Are plasma biomarkers of immune activation predictive of HIV progression: a longitudinal comparison and analyses in HIV-1 and HIV-2 infections? PLoS ONE. 2012;7:e44411.
pubmed: 22970212
pmcid: 3438191
doi: 10.1371/journal.pone.0044411
Habip Z, Sohrabi P, Saribas S, Caliskan R, Demirci M, Karakullukcu A, et al. Neopterin and soluble CD14 levels as indicators of immune activation in cases with low anti-HCV reactivity and true HCV infection. Acta Virol. 2017;61:264–72.
pubmed: 28854790
doi: 10.4149/av_2017_304
Bellmann-Weiler R, Lanser L, Burkert F, Seiwald S, Fritsche G, Wildner S, et al. Neopterin predicts Disease Severity in hospitalized patients with COVID-19. Open Forum Infect Dis. 2021;8:ofaa521.
pubmed: 33442554
doi: 10.1093/ofid/ofaa521
Fuchs D, Hausen A, Kofler M, Kosanowski H, Reibnegger G, Wachter H. Neopterin as an index of immune response in patients with tuberculosis. Lung. 1984;162:337–46.
pubmed: 6527565
doi: 10.1007/BF02715666
Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Mol Immunol. 2005;42:183–94.
pubmed: 15488607
doi: 10.1016/j.molimm.2004.06.017
Spencer ME, Jain A, Matteini A, Beamer BA, Wang N-Y, Leng SX, et al. Serum levels of the Immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of Body Fat. J Gerontol Biol Sci Med Sci. 2010;65A:858–65.
doi: 10.1093/gerona/glq066
Capuron L, Geisler S, Kurz K, Leblhuber F, Sperner-Unterweger B, Fuchs D. Activated Immune System and inflammation in healthy ageing: relevance for Tryptophan and Neopterin Metabolism. Curr Pharm Des. 2014;20:6048–57.
pubmed: 24641220
doi: 10.2174/1381612820666140317110217
Michels EHA, Appelman B, de Brabander J, van Amstel RBE, Chouchane O, van Linge CCA, et al. Age-related changes in plasma biomarkers and their association with mortality in COVID-19. Eur Respir J. 2023;62:2300011.
pubmed: 37080568
pmcid: 10151455
doi: 10.1183/13993003.00011-2023
Statsenko Y, Al Zahmi F, Habuza T, Almansoori TM, Smetanina D, Simiyu GL et al. Impact of Age and Sex on COVID-19 severity assessed from radiologic and clinical findings. Front Cell Infect Microbiol. 2022;11.
Kang S-J, Jung S-I. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52.
Liu Y, Mao B, Liang S, Yang J-W, Lu H-W, Chai Y-H et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Resp J. 2020;55.
Lee K-A, Flores RR, Jang IH, Saathoff A, Robbins PD. Immune Senescence, Immunosenescence and Aging. Front Aging. 2022;3:900028.
pubmed: 35821850
pmcid: 9261375
doi: 10.3389/fragi.2022.900028
Witkowski JM, Fulop T, Bryl E. Immunosenescence and COVID-19. Mech Ageing Dev. 2022;204:111672.
pubmed: 35378106
pmcid: 8975602
doi: 10.1016/j.mad.2022.111672
Zinatizadeh MR, Zarandi PK, Ghiasi M, Kooshki H, Mohammadi M, Amani J, et al. Immunosenescence and inflamm-ageing in COVID-19. Ageing Res Rev. 2023;84:101818.
pubmed: 36516928
doi: 10.1016/j.arr.2022.101818
Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, et al. Serum neopterin, an Immune activation marker, independently predicts Disease Progression in Advanced HIV-1 infection. Clin Infect Dis. 2005;40:853–8.
pubmed: 15736019
doi: 10.1086/427877
Fenollar F, Mediannikov O. Emerging infectious diseases in Africa in the 21st century. New Microbes New Infect. 2018;26:S10–8.
pubmed: 30402238
pmcid: 6205565
doi: 10.1016/j.nmni.2018.09.004